Efficacy and Safety of Pirfenidone for Mitigation of Interstitial Lung Abnormalities in COVID‐19 Patients: A Meta‐Analysis
Pirfenidone therapy may mitigate ILAs and preserve pulmonary function among survivors of COVID-19 pneumonia. Furthermore, pirfenidone exhibited acceptable safety and tolerability profiles.
Authors
- Xiang Fang
- Jinhui Gao
- Heming Sun
- Ziyi Zhang (ORCID: https://orcid.org/0009-0007-5246-632X)
- Jiajia Wang
- Ting Xu
Institutions
- Soochow University (CN)
- Second Affiliated Hospital of Soochow University (CN)
- First Affiliated Hospital of Soochow University (CN)
Publication Details
- Journal
- Canadian Respiratory Journal
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1155/carj/8812779
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00